

0360
M
AS

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED
WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE
AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO:
ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231, ON



01 November 2001

[Handwritten signature]
ATTORNEY FOR APPLICANTS

1, November 2001

DATE

Attorney Docket No. P51160

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Erskine, *et al.* 01 November 2001
Serial No.: 09/912,483 Group Art Unit No.: Unknown
Filed: July 25, 2001 Examiner: Unknown
For: Compounds and Methods for the Treatment of Neoplastic Disease

Assistant Commissioner for Patents
Washington, D.C. 20231

FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 in order to comply with the duty of disclosure. Their inclusion herein should not, however, be construed as an admission that any particular cited reference is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited reference is enclosed, except for those references which are already part of the filewrapper. This statement is being filed within the time period specified in 37 CFR §1.97(b). No fee is required.

Respectfully submitted,

[Handwritten signature]
Edward R. Gimmi
Attorney for Applicants
Registration No. 38,891

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-4478
Facsimile (610) 270-5090
N:\ERG\APPS\P51160\IDS Letter.doc